Most Read Articles
3 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Onsite, lab-free testing of COVID-19 being done in London hospitals

19 Aug 2020

A new, lab-free COVID-19 test is now being distributed to selected hospitals across London. The new test is called COVID Nudge and claims to offer “gold-standard accuracy” and a processing time from sample collection to results in about an hour. [Available at: https://imperialbrc.nihr.ac.uk/2020/06/01/lab-free-covid-19-test-trialled-in-london-hospitals/ Accessed on 13 August 2020]

The availability of this test comes after its approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) in April this year. MHRA is the body which regulates medicines, medical devices and blood components for transfusions in the UK.

As an added benefit, the novel test requires neither pre-processing nor manual steps as the sample is inserted directly into a cartridge, where it is processed immediately. It also incorporates a unique control feature that indicates swab efficacy, and lets the user know if a repeat test is necessary.

The test was developed by Professor Chris Toumazou, of the National Institute for Health Research Imperial Biomedical Research Centre Genetics and Genomics Theme,  Regius Professor of Engineering and chief executive officer of DnaNudge, noted that the traits that make the test groundbreaking are its high level of accuracy and the length of time taken to process a sample, in addition to requiring no manual steps. Toumazou added that COVID Nudge is the only point-of-care test that doesn’t require a laboratory or human interaction. The reliability and speed of sample processing is what makes the new test useful for patients and staff.

The COVID Nudge test is adapted from an existing product introduced last year, the DnaNudge’s DNA test catered for consumers. The results enable users to personalize their health according to their genetic makeup.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.